FASN, fatty acid synthase, 2194

N. diseases: 245; N. variants: 6
Disease: Malignant neoplasm of ovary ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.390 Biomarker disease BEFREE The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model. 29569717 2018
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.390 Biomarker disease BEFREE Dendritic cells educated by FASN<sup>high</sup> OvCa ascites are defective in their ability to present antigens and prime T cells. 30619288 2018
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.390 Biomarker disease BEFREE Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells. 25302649 2015
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.390 AlteredExpression disease BEFREE Fatty acid synthase overexpression: target for therapy and reversal of chemoresistance in ovarian cancer. 25947066 2015
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.390 Biomarker disease BEFREE These findings suggest that FASN plays a critical role in the peritoneal metastasis of ovarian cancer. 24979135 2014
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.390 AlteredExpression disease BEFREE The lipogenic enzyme fatty acid synthase (FASN) is overexpressed in approximately 80% of ovarian carcinomas. 21970855 2011
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.390 Biomarker disease CTD_human Overexpression of fatty acid synthase in Middle Eastern epithelial ovarian carcinoma activates AKT and Its inhibition potentiates cisplatin-induced apoptosis. 21442130 2011
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.390 Biomarker disease BEFREE The study suggests that molecular targeting of FAS and FAK by HO-3867 may be a potential strategy for ovarian cancer therapy. 20713491 2010
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.390 AlteredExpression disease BEFREE Activation of AKT and overexpression of fatty acid synthase (FAS) are frequently observed in human ovarian cancer. 15806173 2005
CUI: C1140680
Disease: Malignant neoplasm of ovary
Malignant neoplasm of ovary 		0.390 AlteredExpression disease BEFREE Here, we have identified a molecular link between FAS and HER2 (erbB-2) oncogene, a marker for poor prognosis that is overexpressed in 30% of breast and ovarian cancers. 15235125 2004